Earnings
Home›Earnings›Analyst Ratings›Zydus Lifesciences hits 52-week high amid FDA inspecti…
Zydus Lifesciences hits 52-week high amid FDA inspection tailwinds
The stock rose to ₹1,232.10 and is up 32% in 2026 so far, ahead of an 18% gain in the Nifty Pharma Index.
Zydus Lifesciences shares hit a fresh 52-week high at ₹1,232.10 on Tuesday, even as the broader market remained under pressure, according to LiveMint Markets.
The stock has gained 32% in 2026 to date, outperforming the Nifty Pharma Index, which is up 18% over the same period.
LiveMint Markets also linked the move to favorable US FDA inspection outcomes, citing that the regulator’s review of the company’s New Jersey office covering pharmacovigilance and post-marketing surveillance concluded with nil observations on 26 September.
The company later reported that its SEZ II manufacturing facility in Ahmedabad inspection closed with one observation and no data impact, and the article points to resilient India growth and a strong innovation pipeline as additional support, while noting US weakness and margin pressure as key risks.